期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

麻醉药物代谢酶CYP45O酶系基因组学研究进展 被引量：2

Cytochrome P450 pharmacogenomics of anesthetics
下载PDF
导出
摘要 遗传多态性是造成个体对药物反应差异的重要因素之一,其中CYP4 5 0酶系的基因多态性可能导致种族间及个体间对同一底物代谢能力的不同。现就镇静安定药、吸入麻醉药、局麻药、镇痛药的药物效应与CYP4 5 0基因多态性的相关性进行综述,为临床个体化给药,实现个体优化治疗提供新思路。
作者 汪国香 方向明 郑汉光
机构地区 浙江大学医学院医学三系麻醉学教研室 杭州市红十字会医院麻醉科
出处 《国外医学（麻醉学与复苏分册）》 2005年第1期39-42,共4页 Foreign Medical Sciences(Anesthesilolgy and Resuscitation)
关键词 P450酶系 基因组学研究 药物代谢酶 CY 基因多态性 药物反应差异 遗传多态性 镇静安定药 吸入麻醉药 个体化给药 药物效应 优化治疗 局麻药 相关性 镇痛药 新思路
分类号 R96 [医药卫生—药理学]
  • 相关文献

参考文献19

  • 1施静艺,陈赛娟.药物基因组学——指导合理用药的基因组学[J].中华医学遗传学杂志,2002,19(2):156-158. 被引量：9
  • 2张迎辉,毛军文,王升启.药物基因组学及其应用[J].国外医学（药学分册）,2002,29(1):18-21. 被引量：11
  • 3Lin YS, Dowling AL, Quigley SD, et al. Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism.Mol Pharmacol, 2002, 62( 1 ): 162-172.
  • 4Floyd MD, Gervasini G, Masica AL, et al. Genotype-phenotype associa tions for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women. Pharmacogenetics, 2003, 13(10) :595-606.
  • 5Williams JA, Cook J, Hurst SI. A significant drug-metabolizing role for CYP3A5? Drug Metab Dispos,2003,31(12): 1526-1530.
  • 6Shih PS, Huang JD. Phannacokinetics of midazolam and 1 '-hydroxymidazolan in Chinese with different CYP3A5 genotypes, Drug Metab Dispos, 2002,30(12): 1491-1496.
  • 7Niemi M, BacKman .JT, Fromm MF, et al. Phamacokinetic interactions with rifampicin: clinical relevance. Clin Pharmacokinet, 2003,42 (9): 819-850.
  • 8Spracklin DK, Hankins DC, Fisher JM, et al. Cytochrome P450 2El is theprincipal catalyst of human oxidative halothane metabolism in vitro. J Phar macol Exp Ther, 1997,281 ( 1 ): 400-411 .
  • 9Garton KJ, Yuen P, Meinwald J, et al. Stereoselective metabolism of enflurane by human liver cytochrome P450 2El. Drug Metab Dispos, 1995,23 (12): 1426-1430.
  • 10Kharasch ED. Biotransformation of sevoflmane. Anesth Analg, 1995,81 (6 Suppl): S27-S38.

二级参考文献34

  • 1Ferrari P. Pharmacogenomics: a new approach to individual therapy of hypertension[J] ? Curr Opin Nephrol Hypertens,1998, 7(2) :217 - 222.
  • 2Diasio RB,Johnson MR. The role of pharmacogenetics and pharmacogenomics in cancer chemotherapy with 5-fluorouracil[J]. Pharmacology, 2000, 61(3):199-203.
  • 3March R. Pharmacogenomics: the genomics of drug response[J]. Yeast, 2000, 17(1):16-21.
  • 4Marshall A. Genset-Abbott deal heralds pharmacogenomics era[J]. Nat Biotechnol, 1997, 15(9) :829 - 830.
  • 5Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics[J]. Science,1999, 286(5439) :487 - 491.
  • 6Destenaves B, Thomas F. New advances in pharmacogenomics[J]. Curr Opin Chem Biol , 2000, 4 (4): 440-444.
  • 7Bailey DS,Bondar A,Furness LM. Pharmacogenomics- it′s not just pharmacogenetics[J]. Curr Opin Biotechnol, 1998,9(6):595-601.
  • 8Persing BF, Cheek DJ. Pharmacogenomics [J]. Nurs Clin North Am, 2000, 35(4): 975 - 980.
  • 9Kao SL, Chong SS, Lee CG. The role of single nucleotide polymorphisms (SNPs) in understanding complex disorders and pharmacogenomics [J]. Ann Acad Med Singapore,2000, 29(3) :376- 382.
  • 10Bhagat K, Nhachi CF. Pharmacogenomics: today, tomorrow and beyond[J]. Cent Afr J Med, 1999, 45(12):335-337.

共引文献16

同被引文献39

  • 1Marzolini C,Paus E,Buclin T,et al. Polymorphisms in human MDR1 (P-glycoprotein) : recent advances and clinical relevance[J]. Clin Pharmacol Ther, 2004,75 ( 1 ) : 13-33.
  • 2Lotseh J,Skarke C, Liefhold J,et al. Genetic predictors of the clinical response to opioid analgesics[J]. Clin Pharmacokinet, 2004,43(14) :983-1013.
  • 3Lotsch J,Geisslinger G. Relevance of frequent μ- opioid receptor polymorphisms for opioid activity in healthy volunteers [J]. Pharmacogenomics J, 2006,6 (3) : 200-210.
  • 4Bonin R P,Orser B A. GABAA receptor subtypes underlying general anesthesia[J]. Pharmacol Biochem Behav, 2008, 90 (1):105-112.
  • 5Nishikawa K,Jenkins A, Paraskevakis l,et al.Volatile anesthetic actions on the GABAA receptors: contrasting effects of al(S270) and β2 (N265) point mutations[J]. Neuropharma cology,2002,42(3):337-345.
  • 6Jurd R,Arras M,Lambert S,et al. General anesthetic actions in vivo strongly attenuated by a point mutation in the GABAA receptor β3 subunit[J]. FASEB J, 2003,17(2) : 250- 252.
  • 7Girard T,Treves S,Voronkov E,et al. Molecular genetic tes ring for malignant hyperthermia susceptibility[J]. Anesthesiology, 2004,100 (5) : 1076-1080.
  • 8Sambuughin N,Sei Y, Gallagher K L, et al. North American malignant hyperthermia population: screening of the ryanodine receptor gene and identification of novel mutations [J]. Anesthesiology, 2001,95 (3) : 594-599.
  • 9Girard T,Kindler C H. Pharmacogenetics and anaesthesiology [J]. Curr Pharmacogenomics,2004,2(2) : 119-135.
  • 10Kharasch E D, Walker A, Isoherranen N, et al. Influence of CYP3A5 genotype on the pharmacokinetics and pharmaeody namics of the cytochrome P4503A probes alfentanil and midazolam[J]. Clin Pharmacol Ther,2007,82(4) :410-426.

引证文献2

国外医学（麻醉学与复苏分册）
2005年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部